Modulateurs du GABA

Applications A metabolic intermediate in nucleic acid metabolism.
References Yoon, K., et al.: Nat. Prod. Sci., 14, 254 (2008), Ramazzina, I., et al.: J. Biol. Chem., 283, 23295 (2008), Kim, K., et al.: J. Mol. Biol., 387, 1067 (2009),

Applications Potassium bromide is an ionic compound that is commonly used in chemistry to form a pellet that can be used to analyze a number of compounds by means of infrared spectroscopy. Potassium bromide is also used as an anticonvulsant to treat refractory seizures in humans and dogs.
References Kirkland, J.: Anal. Chem., 27, 1537 (1955); Korinthenberg, R., et al.: J. Child Neuro., 22, 414 (2007); Wilberley, S., et al.: Anal. Chem., 29, 210 (1957); Yohn, S., et al.: J. Am. Vet. Med. Ass., 201, 468 (1992)

Impurity Valproic Acid USP Related Compound B
Applications A constitutional isomer of Valproic acid; a potent anticonvulsant. Sodium valproate impurity C. Valproic Acid USP Related Compound B.
References Levy, R., et al.: Pharm. Res., 8, 551 (1991), Barton, M., et al.: Epilepsy Res., 47, 217 (2001), Fox, A., et al.: Pain, 105, 355 (2003), Archer, D., et al.: Anesth. Analg., 104, 180 (2007),

Applications Anticholinergic. Antispasmodic.
References Fujita, et al.: J. Labelled Compd., 9, 149 (1972), Tanaka, et al.: J. Pharm. Soc. Jpn., 92, 510 (1972), Kawamoto H., et al.: Arzneim.-Forsch., 35, 1475 (1985),

Stability Light Sensitive
Applications Prifinium Bromide is a synthetic antispasmodic drug; parasympatholytic. Prifinium Bromide is used as a quartenary anticholinergic agent.
References Kumada, S. et al.: Arzneim.-Forsch., 20, 237 (1970); Nakai, T. et al.: Arzneim.-Forsch., 20, 1112 (1970); Bettini, V. et al.: Farm. Ed. Prat., 33, 392 (1978);

Impurity Valproic Acid USP Related Compound A
Applications Diallylacetic Acid (Valproic Acid USP Related Compound A), is a metabolite of Valproic Acid (V094750) as anticonvulsant agents. It can also be used for the synthesis of Velbanamine.
References Liu, H., et al.: Beilstein J. Org. Chem., 9, 983 (2013); Loscher, W., Prog. Neurobiol., 58, 31 (1999); Netzeva, T., et al.: Pharmac. Res., 17, 727 (2000);